Huntington's disease phenotypes are improved via mTORC1 modulation by small molecule therapy.

Area of Science:

• Neuroscience
• Pharmacology
• Genetics

Background:

• Huntington's Disease (HD) is a neurodegenerative disorder with significant mortality from pneumonia and cardiac issues.
• Dysregulation of the mTORC1 pathway is observed in HD models and human tissues.
• Genetic approaches to correct mTORC1 deficits show limited therapeutic potential.

Purpose of the Study:

• To evaluate NV-5297, a novel small molecule activator of the mTORC1 pathway, for its efficacy in improving HD phenotypes.
• To assess the impact of NV-5297 on central and peripheral manifestations of HD in a relevant animal model.

Main Methods:

• Utilized the N171-82Q transgenic mouse model of Huntington's Disease.
• Administered NV-5297 orally for six weeks.
• Assessed effects on mTORC1 pathway activation, striatal volume, motor learning, cardiac function, fibrosis, and survival under stress.

Main Results:

• NV-5297 successfully activated the mTORC1 pathway.
• Treatment led to increased striatal volume and improved motor learning.
• Enhanced heart contractility, reduced cardiac fibrosis, and improved survival were observed, particularly under isoprenaline-induced cardiac stress.

Conclusions:

• mTORC1 pathway activation represents a viable therapeutic strategy for Huntington's Disease.
• NV-5297 demonstrates potential as a drug candidate for treating both central and peripheral HD symptoms.
• The findings support NV-5297's broader applicability to mTORC1-deficit related diseases.